Thess, Andreas

Developing mRNA-vaccine technologies

Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology

RNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Cited by 622

Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals

Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy

RNA Interference and Gene DeliveryRNA and protein synthesis mechanisms

Cited by 513

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology

Influenza Virus Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 464

A novel, disruptive vaccination technology: Self-adjuvanted RNActive ® vaccines

Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 223

mRNA mediates passive vaccination against infectious agents, toxins, and tumors

Thran, M., Mukherjee, J., Pönisch, M., Fiedler, K., Thess, A., Mui, B. L., Hope, M. J., Tam, Y. K., Horscroft, N., Heidenreich, R., et al. (2017) · EMBO Molecular Medicine

RNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Cited by 166

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

Fotin‐Mleczek, M., Zanzinger, K., Heidenreich, R., Lorenz, C., Thess, A., Duchardt, K. M., & Kallen, K. (2012) · The Journal of Gene Medicine

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 103

Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses

Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2022) · Vaccines

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 22

Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homogeneous and heterogenous neutralising antibody responses

Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory)

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 18